Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Biogen Stock: Is BIIB Outperforming the Healthcare Sector?

Cambridge, Massachusetts-based Biogen Inc. (BIIB) is a biotechnology company that discovers, develops, and delivers innovative therapies for serious neurological and neurodegenerative diseases. It is valued at a market cap of $27.7 billion. 

Companies worth $10 billion or more are typically classified as “large-cap stocks,” and Biogen fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the drug manufacturers - general industry. Beyond its core neurology focus, the company is actively expanding its pipeline across immunology and rare diseases, leveraging cutting-edge modalities like antisense oligonucleotides (ASOs) to address high unmet medical needs.

Fundamentals

See More
  • Market Capitalization, $K 27,954,656
  • Shares Outstanding, K 146,759
  • Annual Sales, $ 9,891 M
  • Annual Income, $ 1,293 M
  • EBIT $ 2,377 M
  • EBITDA $ 3,451 M
  • 60-Month Beta 0.15
  • Price/Sales 2.80
  • Price/Cash Flow 8.32
  • Price/Book 1.51

Options Overview Details

View History
  • Implied Volatility 36.56% (+0.41%)
  • Historical Volatility 38.01%
  • IV Percentile 62%
  • IV Rank 24.16%
  • IV High 64.86% on 04/09/25
  • IV Low 27.55% on 01/07/26
  • Expected Move (DTE 1) 5.87 (3.15%)
  • Put/Call Vol Ratio 0.30
  • Today's Volume 2,212
  • Volume Avg (30-Day) 1,043
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 51,557
  • Open Int (30-Day) 51,469
  • Expected Range 180.26 to 191.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 35 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 3.05
  • Number of Estimates 26
  • High Estimate 4.68
  • Low Estimate 1.66
  • Prior Year 3.02
  • Growth Rate Est. (year over year) +0.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
181.24 +2.97%
on 03/06/26
200.29 -6.82%
on 02/17/26
-8.87 (-4.54%)
since 02/12/26
3-Month
160.36 +16.38%
on 01/20/26
202.41 -7.80%
on 02/06/26
+12.53 (+7.20%)
since 12/12/25
52-Week
110.04 +69.60%
on 04/09/25
202.41 -7.80%
on 02/06/26
+46.44 (+33.13%)
since 03/12/25

Most Recent Stories

More News
Biogen Stock: Is BIIB Outperforming the Healthcare Sector?

Biogen has outperformed its sector peers recently, and analysts remain moderately optimistic about the stock’s prospects.

XLV : 150.80 (-1.34%)
AMGN : 370.96 (-1.77%)
BIIB : 185.92 (-2.39%)
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy ...

BIIB : 185.92 (-2.39%)
Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks

Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks

BIIB : 185.92 (-2.39%)
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA,...

BIIB : 185.92 (-2.39%)
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– ...

STOK : 35.96 (-5.22%)
BIIB : 185.92 (-2.39%)
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support...

STOK : 35.96 (-5.22%)
BIIB : 185.92 (-2.39%)
Is Vertex Stock Outperforming the Dow?

Despite underperforming the Dow Jones Industrial Average over the past year, Vertex continues to earn moderate bullish support from analysts.

VRTX : 479.32 (-2.65%)
$DOWI : 46,919.56 (-1.05%)
BIIB : 185.92 (-2.39%)
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine,...

STOK : 35.96 (-5.22%)
BIIB : 185.92 (-2.39%)
3 Value Stocks Walking a Fine Line

3 Value Stocks Walking a Fine Line

PANL : 7.13 (-1.25%)
WEX : 164.18 (+2.31%)
BIIB : 185.92 (-2.39%)
What Are Wall Street Analysts' Target Price for Biogen Stock?

Analysts are maintaining a generally positive outlook on Biogen's shares, noting recent stock strength and solid operational results.

$SPX : 6,714.40 (-0.91%)
IBB : 166.80 (-2.38%)
BIIB : 185.92 (-2.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 198.58
2nd Resistance Point 195.79
1st Resistance Point 193.13
Last Price 185.92
1st Support Level 187.68
2nd Support Level 184.89
3rd Support Level 182.23

See More

52-Week High 202.41
Last Price 185.92
Fibonacci 61.8% 167.12
Fibonacci 50% 156.23
Fibonacci 38.2% 145.33
52-Week Low 110.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar